1. Home
  2. PTLE vs BOLD Comparison

PTLE vs BOLD Comparison

Compare PTLE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PTLE

PTL LTD Ordinary Shares

N/A

Current Price

$9.59

Market Cap

60.4M

Sector

Energy

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.39

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PTLE
BOLD
Founded
2013
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
60.4M
54.5M
IPO Year
2024
2024

Fundamental Metrics

Financial Performance
Metric
PTLE
BOLD
Price
$9.59
$2.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
105.8K
★ 155.1K
Earning Date
11-15-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.96
52 Week High
$16.17
$3.16

Technical Indicators

Market Signals
Indicator
PTLE
BOLD
Relative Strength Index (RSI) 63.52 50.16
Support Level $9.27 $2.37
Resistance Level $10.65 $2.71
Average True Range (ATR) 0.74 0.13
MACD 0.06 0.02
Stochastic Oscillator 77.70 70.31

Price Performance

Historical Comparison
PTLE
BOLD

About PTLE PTL LTD Ordinary Shares

PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, serving the Asia Pacific market. The company's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers on time; and handling disputes, mainly concerning quality and quantity issues on marine fuel. The company derives its maximum revenue from Hong Kong.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: